Skye Bioscience Inc (SKYE)

[IHuser]

Skye Bioscience, Inc., formerly Emerald Bioscience, Inc., is a biopharmaceutical company, which is engaged in engineering cannabinoid derivatives to treat glaucoma and other diseases. The Company is focused on discovery, development, and commercialization of cannabinoid-derived therapeutics, with clinical and commercial differentiation for the treatment of glaucoma diseases. Its programs include THCVHS and CBDVHS. The Company's lead candidate, THCVHS, a prodrug of tetrahydrocannabinol (THC), is a topical formulation under development for the treatment of glaucoma and ocular hypertension (OHT). It chemically modifies THC to create a unique synthetic molecule with the intent to realize the known positive effects of THC. CBDVHS is a prodrug of cannabidiol (CBD) that has demonstrated biological activity in prodrug form (CBDVHS) and as native (natural) CBD. The Company has chemically-modified the CBD molecule to improve on its known positive effects.